Sherko Kümmel

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2.1K citations

Medicine, Immunology, Oncology +14

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Breast Oncology +12

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14